As a result of the subscription of L-series shares and M1-series shares carried out in May, NanoGroup concluded share subscription agreements for a total issue price of PLN 4.7 million, the company said. The funds raised will fund the next stage of research and development of the NanOX system, which is a device and NanOX fluid for extracorporeal storage of organs for transplantation.
“May’s fully successful share issuance is one element of the implementation of a broad plan to raise financing to enable NanoGroup to intensify its R&D work, particularly in the development of the Nanosanguis-led project, the NanOX system. As stipulated in a separate investment agreement with eCapital Sp. z o.o. owned by Mr. Michal Lach, the next phases of the project’s development, and thus the possibility of raising additional funds, have been scheduled until the end of 2025. The total value of the financing we can raise as a result of the activities undertaken in recent months is nearly PLN 10 million, and our further plans include. Obtaining research and development funding from EU funds. We are confident that all these activities will result in bringing the project to the phase I clinical trial stage, and will also enable intensification of activities related to acquiring an industry partner,” said CEO Przemyslaw Mazurek, quoted in the release.
NanoGroup carried out a subscription for series L ordinary bearer shares. The subscription included 3,699,490 securities. Share subscription agreements have been executed for all of them and all shares have been paid for. The issue value of the shares was PLN 3,699,490. Also issued were 952,381 series M1 shares for PLN 1 million. As a result of the issues, NanoGroup raised nearly PLN 4.7 million, it recalled.
The NanOX project, being developed by subsidiary Nanosanguis, is a proprietary system consisting of a specialized NanOX Recovery Box and NanOX perfusion fluid, which is used for extracorporeal storage of organs for transplantation. Current work is focused on performing a successful autotransplantation of a pig kidney.
NanoGroup is a commercial research organization, formed as a result of the combination of a team of professionals from the fields of biotechnology, medicine and business. The company was established in 2016 to consolidate into a single group of special-purpose companies with projects centered around nanotechnology. In 2017, the company debuted on the WSE.